Cabbacis (CABI) Files H1 2026 1-SA, Updates Studies
Cabbacis filed its Semiannual Report on Form 1-SA for the six months ended June 30, 2026 and provided updates on iBLEND and X95 development, including an ongoing Switzerland study and plans for a larger U.S. study and FDA filings.Material DetailsContext by AI AnalystThis is an early-stage update: a…